PREVAIL IV (Q5) Double-Blind Randomized Two-Phase Placeb

Project: Research project

Project Details


PREVAIL IV (Q5) Double-Blind Randomized Two-Phase Placebo Controlled Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus and Safety in Male Ebola Survivors with Evidence of Ebola Virus Persistence in Semen
Effective start/end date8/13/169/25/21


  • Leidos Biomedical Research, Inc.


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.